Prevalence and diagnostic performance of iron deficiency in polycythemia

References

• Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15), doi:10.1038/s41408-018-0054-y.
   PubMed Web of Science ®Google Scholar
• Kremyanskaya M, Mascarenhas J, Hoffman R. Why does my patient have erythrocytosis? Hematol Oncol Clin North Am. 2012;26(2):267–283. doi:10.1016/j.hoc.2012.02.011.
   PubMed Web of Science ®Google Scholar
• Brodsky I, Kahn SB, Brady LW. Polycythaemia vera: differential diagnosis by ferrokinetic studies and treatment with busulphan (myleran*). Brit J Haemat. 1968;14(4):351–361. doi:10.1111/j.1365-2141.1968.tb06987.x.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Muehlhausen K, et al. Polycythemia rubra vera versus secondary polycythemias. A clinicopathological evaluation of distinctive features in 199 patients. Pathol Res Pract. 2001;197(2):77–84. doi:10.1078/0344-0338-5710013.
   PubMed Web of Science ®Google Scholar
• Gianelli U, Iurlo A, Vener C, et al. The significance of bone marrow biopsy and JAK2 V617F mutation in the differential diagnosis between the “early” prepolycythemic phase of polycythemia vera and essential thrombocythemia. Am J Clin Pathol. 2008;130(3):336–342. doi:10.1309/6BQ5K8LHVYAKUAF4.
   PubMed Web of Science ®Google Scholar
• Ginzburg YZ, Feola M, Zimran E, et al. Dysregulated iron metabolism in polycythemia vera: etiology and consequences. Leukemia. 2018;32(10):2105–2116. doi:10.1038/s41375-018-0207-9.
   PubMed Web of Science ®Google Scholar
• Hung SH, Lin HC, Chung SD. Association between venous thromboembolism and iron-deficiency anemia. Blood Coagul Fibrinolysis. 2015;26(4):368–372. doi:10.1097/MBC.0000000000000249.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544.
   PubMed Web of Science ®Google Scholar
• Ning S, Zeller MP. Management of iron deficiency. Hematology Am Soc Hematol Educ Program. 2019;2019(1):315–322. doi:10.1182/hematology.2019000034.
   PubMedGoogle Scholar
• Moulard O, Mehta J, Fryzek J, et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92(4):289–297. doi:10.1111/ejh.12256.
   PubMed Web of Science ®Google Scholar
• Deadmond MA, Smith-Gagen JA. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011. J Cancer Res Clin Oncol. 2015;141(12):2131–2138. doi:10.1007/s00432-015-1983-5.
   PubMed Web of Science ®Google Scholar
• Marneth AE, Mullally A. The molecular genetics of myeloproliferative neoplasms. Cold Spring Harb Perspect Med. 2020;10(2):a034876. doi:10.1101/cshperspect.a034876.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Lasho TL, et al. Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2020;189(2):291–302. doi:10.1111/bjh.16380.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc. 2003;78(2):174–194. doi:10.4065/78.2.174.
   PubMed Web of Science ®Google Scholar
• Dickstein JI, Vardiman JW. Hematopathologic findings in the myeloproliferative disorders. Semin Oncol. 1995;22(4):355–373.
   PubMed Web of Science ®Google Scholar
• Pearson TC. Diagnosis and classification of erythrocytoses and thrombocytoses. Baillieres Clin Haematol. 1998;11(4):695–720. doi:10.1016/S0950-3536(98)80035-8.
   PubMedGoogle Scholar
• Murphy S. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia. Semin Hematol. 1999;36(1 Suppl 2):9–13.
   PubMed Web of Science ®Google Scholar
• Pearson TC, Messinezy M. The diagnostic criteria of polycythaemia rubra vera. Leuk Lymphoma. 1996;22(Suppl 1):87–93.
   PubMed Web of Science ®Google Scholar
• Kassebaum NJ, GBD 2013 Anemia Collaborators 2016. The global burden of anemia. Hematol Oncol Clin North Am; 30(2):247–308. doi:10.1016/j.hoc.2015.11.002.
   PubMed Web of Science ®Google Scholar
• Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011–1023. doi:10.1056/NEJMra041809.
   PubMed Web of Science ®Google Scholar
• De Domenico I, Lo E, Ward DM, et al. Hepcidin-induced internalization of ferroportin requires binding and cooperative interaction with Jak2. Proc Natl Acad Sci USA. 2009;106(10):3800–3805. doi:10.1073/pnas.0900453106.
   PubMed Web of Science ®Google Scholar
• Kambali S, Taj A. Polycythemia vera masked due to severe iron deficiency anemia. Hematol Oncol Stem Cell Ther. 2018;11(1):38–40. doi:10.1016/j.hemonc.2016.08.007.
   PubMedGoogle Scholar
• Aladağ E, Aksu S, Demiroğlu H, et al. Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency. Turk J Med Sci. 2019;49(5):1560–1563. doi:10.3906/sag-1907-67.
   PubMed Web of Science ®Google Scholar
• Albayrak C, Tarkun P, Birtaş Ateşoğlu E, et al. The role of hepcidin, GDF15, and mitoferrin-1 in iron metabolism of polycythemia vera and essential thrombocytosis patients. Turk J Med Sci. 2019;49(1):74–80. doi:10.3906/sag-1803-13.
   PubMed Web of Science ®Google Scholar
• Schächner E, Ronen M, Pinkhas J, et al. Iron absorption in patients with polycythemia vera. Eur J Nucl Med. 1978;3(2):125–127. doi:10.1007/BF00251637.
   PubMedGoogle Scholar
• Khalil S, Delehanty L, Grado S, et al. Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. J Exp Med. 2018;215(2):661–679. doi:10.1084/jem.20170396.
   PubMed Web of Science ®Google Scholar
• Marchioli R, Vannucchi AM, Barbui T. Treatment target in polycythemia vera. N Engl J Med. 2013;368(16):1554), doi:10.1056/NEJMc1301262.
   PubMedGoogle Scholar
• Vannucchi AM, Kiladjian JJ, Griesshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(5):426–435. doi:10.1056/NEJMoa1409002.
   PubMed Web of Science ®Google Scholar
• Salem HH, Van der Weyden MB, Young IF, et al. Pruritus and severe iron deficiency in polycythaemia vera. Br Med J (Clin Res Ed). 1982;285(6335):91–92. doi:10.1136/bmj.285.6335.91.
   PubMedGoogle Scholar
• Casu C, Nemeth E, Rivella S. Hepcidin agonists as therapeutic tools. Blood. 2018;131(16):1790–1794. doi:10.1182/blood-2017-11-737411.
   PubMed Web of Science ®Google Scholar